KR870006902A - 백일해 항원의 정제방법 - Google Patents

백일해 항원의 정제방법 Download PDF

Info

Publication number
KR870006902A
KR870006902A KR870000366A KR870000366A KR870006902A KR 870006902 A KR870006902 A KR 870006902A KR 870000366 A KR870000366 A KR 870000366A KR 870000366 A KR870000366 A KR 870000366A KR 870006902 A KR870006902 A KR 870006902A
Authority
KR
South Korea
Prior art keywords
ciliated
lpf
separating
fha
aggregate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR870000366A
Other languages
English (en)
Other versions
KR950010323B1 (ko
Inventor
로빈슨 앤드류
아이안 아이론스 로렌스
Original Assignee
원본미기재
파블릭 헬스 래보레이토리 써어비스 보드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 파블릭 헬스 래보레이토리 써어비스 보드 filed Critical 원본미기재
Publication of KR870006902A publication Critical patent/KR870006902A/ko
Application granted granted Critical
Publication of KR950010323B1 publication Critical patent/KR950010323B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K2039/10Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82Proteins from microorganisms
    • Y10S530/825Bacteria

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

내용 없음.

Description

백일해 항원의 정제방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도 pH 6.5의 0.1M인산-0.5M NaCl 완충액에 의한 하이드록실인회석 크로마토그래피로부터 FHA의 용리기록.
제2도 pH 7.2의 0.05M인산-0.5M NaCl 완충액에 의한 세파로스 CL-6B 크로마토그래피로부터 FHA의 용리기록.

Claims (9)

  1. (a) 세포내의 배양균 및 상등액 분설을 분리하고, (b) 상등액 분설을 농축시키고, (c) 농축된 상등액 분설을 분별하여 LPF 및 FHA를 함유한 분설을 분리시키고, (d) 세포의 분설로부터 최소한 하나의 섬모형 응집원을 분리시키는 것으로 구성되는 Bordetella pertussis의 액체 배양균으로부터 임파구증가 조장 인자(LPF), 사상체의 혈구응집소(FHA) 및 최소한 하나의 섬모형 응집원을 제조하는 방법.
  2. 제1항에 있어서, 단계(d)에서 분리된 섬모형 응집원이 최소한 하나의 응집원 2,3,4,5 및 6을 포함하는 것인 방법.
  3. 제1항에 있어서, 단계(d)에서 분리된 섬모형 응집원이 최소한 응집원 2 및 3(Ag2+3)으로 구성되는 것인 방법.
  4. 제3항에 있어서, 분리된 응집원이 부가적으로 하나 이상의 응집원 4,5 및 6을 포함하는 것인 방법.
  5. 전술한 항의 어느 한항에 있어서, 분리단계(a)를 pH 7.0이상에서 행하는 방법.
  6. 제5항에 있어서, 분리단계(a)를 pH 7.5-9.0범위에서 행하는 방법.
  7. 전술한 항의 어느 한항에 있어서, 단계(b)에서 상등액을 처음 부피의 50%이하로 및 바람직하게는 25%이하로 농축시키는 방법.
  8. 전술한 항의 어느 한항에 있어서, 단계(c)에서 LPF를 함유한 분설을 페튄세파로스(fetuin sepharose)에 흡착시킨 다음 염화마그네슘 완충액으로 용리하여 정제하는 방법.
  9. 제1항 내지 제8항의 어느 한항에 따라 제조한 (i) LPF, (ii) FHA 및 (iii) 최소한 하나의 섬모형 응집원이 혼합되어 있고, LPF, FHA 및 최소한 하나의 섬모형 응집원이 혼합하기전 또는 후에 해독된, 임파구증가 조장인자(LPF), 사상체의 혈구응집소(FHA) 및 최소한 하나의 섬모형 응집원으로 구성된 왁진 조성물의 제조방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019870000366A 1986-01-20 1987-01-19 백일해 항원의 정제 방법 Expired - Lifetime KR950010323B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8601279 1986-01-20
GB868601279A GB8601279D0 (en) 1986-01-20 1986-01-20 Purification of pertussis antigens

Publications (2)

Publication Number Publication Date
KR870006902A true KR870006902A (ko) 1987-08-13
KR950010323B1 KR950010323B1 (ko) 1995-09-14

Family

ID=10591636

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019870000366A Expired - Lifetime KR950010323B1 (ko) 1986-01-20 1987-01-19 백일해 항원의 정제 방법

Country Status (11)

Country Link
US (1) US4784589A (ko)
EP (1) EP0231083B1 (ko)
JP (1) JP2538224B2 (ko)
KR (1) KR950010323B1 (ko)
CN (1) CN1028206C (ko)
AT (1) ATE92335T1 (ko)
AU (1) AU592727B2 (ko)
CA (1) CA1280693C (ko)
DE (1) DE3786806T2 (ko)
DK (1) DK172936B1 (ko)
GB (1) GB8601279D0 (ko)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1337859C (en) * 1987-04-24 1996-01-02 Masashi Chazono Method for culturing bordetella pertussis, a pertussis toxoid and a pertussis vaccine
GB8807860D0 (en) * 1988-04-05 1988-05-05 Connaught Lab Pertussis vaccine
CA1341123C (en) * 1988-10-27 2000-10-17 David A. Relman Filamentous hemagglutinin of b. pertussis
JP2706792B2 (ja) * 1988-11-29 1998-01-28 財団法人化学及血清療法研究所 百日咳毒素のトキソイド化法
GB8910570D0 (en) * 1989-05-08 1989-06-21 Wellcome Found Acellular vaccine
EP0427462B1 (en) 1989-11-06 1996-02-14 SMITHKLINE BEECHAM BIOLOGICALS (S.A.), formerly SMITHKLINE BIOLOGICALS (S.A.) Process
US5391715A (en) * 1989-11-06 1995-02-21 Smithkline Beecham Biologicals Method for isolating and purifying bordetella pertussis antigenic factors
ATE129159T1 (de) * 1990-02-12 1995-11-15 Smithkline Beecham Biolog Impfstoff.
EP0484621A3 (en) * 1990-07-11 1992-08-26 American Cyanamid Company Efficacious vaccines against bordetella pertussis comprising a combination of individually purified pertussis antigens
US5445817A (en) * 1992-08-21 1995-08-29 The United States Of America As Represented By The Department Of Health And Human Services Pertussis toxin used as a carrier protein with non-charged saccharides in conjugate vaccines
US6051240A (en) * 1994-04-28 2000-04-18 Takeda Chemical Industries, Ltd. Method of separating protective components of Bordetella pertussis
ATE221081T1 (de) * 1995-05-04 2002-08-15 Aventis Pasteur Azelluläre pertussis-impfstoffe und verfahren zu deren herstellung
US7091311B2 (en) * 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
KR20050093759A (ko) 2002-09-18 2005-09-23 오르토-맥네일 파마슈티칼, 인코퍼레이티드 혈소판 및 조혈 줄기세포의 생산을 증가시키는 방법
AP2015008702A0 (en) 2013-03-08 2015-09-30 Crucell Holland Bv Acellular pertussis vaccine
CN110358802B (zh) * 2019-08-16 2021-06-18 长春百克生物科技股份公司 一种去除百日咳组分菌毛蛋白2/3内毒素的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4247452A (en) * 1978-03-01 1981-01-27 The Secretary Of State For Defence In Her Britannic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland Purification of pertussis haemagglutinins
JPS5750925A (en) * 1980-09-12 1982-03-25 Takeda Chem Ind Ltd Preparation of pertussis toxoid
US4474758A (en) * 1981-11-19 1984-10-02 American Cyanamid Company Haemophilus influenzae type b and pertussis outer membrane component combined vaccine
HU188847B (en) * 1983-02-22 1986-05-28 Human Oltoanyagtermeloe Es Kutato Intezet,Hu Process for producing liophylized combined vaccines
CA1213234A (en) * 1983-03-30 1986-10-28 Akihiro Ginnaga Method for the production of ha fraction containing protective antigens of bordetella pertussis and pertussis vaccine
US4551429A (en) * 1983-09-15 1985-11-05 American Home Products Corporation Stimulation of antigen production by Bordetella pertussis
JPS6098988A (ja) * 1983-11-01 1985-06-01 Chemo Sero Therapeut Res Inst Lpf−haの精製法
CA1237998A (en) * 1984-04-14 1988-06-14 Akihiro Ginnaga Method for purification of filamentous hemagglutinin

Also Published As

Publication number Publication date
DE3786806D1 (de) 1993-09-09
AU592727B2 (en) 1990-01-18
DK27287D0 (da) 1987-01-19
EP0231083B1 (en) 1993-08-04
JPS62234031A (ja) 1987-10-14
EP0231083A2 (en) 1987-08-05
CN1028206C (zh) 1995-04-19
US4784589A (en) 1988-11-15
CN87100399A (zh) 1987-09-09
DE3786806T2 (de) 1993-12-09
AU6766487A (en) 1987-07-23
JP2538224B2 (ja) 1996-09-25
DK27287A (da) 1987-07-21
GB8601279D0 (en) 1986-02-26
DK172936B1 (da) 1999-10-11
EP0231083A3 (en) 1988-06-08
ATE92335T1 (de) 1993-08-15
KR950010323B1 (ko) 1995-09-14
CA1280693C (en) 1991-02-26

Similar Documents

Publication Publication Date Title
KR870006902A (ko) 백일해 항원의 정제방법
AU5504386A (en) Purification of immunoglobulin g
Hirashima et al. Formation of IgE-binding factors by rat T lymphocytes. III. Mechanisms of selective formation of IgE-suppressive factors by treatment with complete Freund's adjuvant.
DE58907555D1 (de) Verfahren zur Anreicherung der Blutgerinnungsfaktoren II, VII, IX und X.
KR850001284A (ko) 키브델로스포렌지움 애리덤(kibdelosporangium aridum)쉬어리(shearer)젠.노브., 에스.피.노브.(gen. nov., sp. nov.)atcc 39323에 의해 생산되는 항생물질들
KR880012238A (ko) 백일해균의 배양방법, 백일해 톡소이드 및 백일해 백신
Köck et al. Purification of human interleukin 1 by high-performance liquid chromatography
DE3585416D1 (de) Verfahren zur herstellung eines biologischen stoffes.
AU7955687A (en) Method for purification of antibodies
Dafni et al. Nature of initial damage to Ehrlich ascites cells caused by Prymnesium parvum toxin
ATE341617T1 (de) Prozess zur reinigung von vitamin k abhängigen koagulationsfaktoren durch chromatographie
EP0115284A3 (en) Tissue culture medium
Lillich et al. Analysis of the intracellular amino acid pool and proteins from whole cells of Rhizobium japonicum
AU6659390A (en) Methods for utilizing cell lines which lack human class ii histocompatibility antigens
JPS5565A (en) Microbial preparation of pristanol and/or pristanediol
Ip et al. Separation of asymmetrical hybrid hemoglobins by anaerobic cation-exchange high-performance liquid chromatography
White et al. The biosynthesis of plasmodial myosin during starvation of Physarum polycephalum
McDonald et al. Apparent molecular weight distribution in raw and treated wastewaters
KR850001537A (ko) 림포톡신 및 림포톡신- mRNA의 제조방법
IT1176630B (it) Chelati naturali per la separazione di radionuclidi
JPS5750892A (en) Microbial preparation of valeric acid derivative
Harada et al. A new method for typing haptoglobin in bloodstains using immobilized allo A lectin
JPS5548395A (en) Antitumor substance verticillomycin and its preparation
Humphrey The L-4946 leukemia in the CF1 mouse
KR890009416A (ko) 정제된 백일해 특소이드의 제조방법

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19870119

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19920118

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19870119

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19950429

Patent event code: PE09021S01D

G160 Decision to publish patent application
PG1605 Publication of application before grant of patent

Comment text: Decision on Publication of Application

Patent event code: PG16051S01I

Patent event date: 19950814

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 19951130

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 19960216

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 19960216

End annual number: 3

Start annual number: 1

PR1001 Payment of annual fee

Payment date: 19990219

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 19990901

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20000908

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20010906

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20020911

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20030915

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20040902

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20050914

Start annual number: 11

End annual number: 11

FPAY Annual fee payment

Payment date: 20060612

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20060612

Start annual number: 12

End annual number: 12

EXPY Expiration of term
PC1801 Expiration of term